NTRA

Natera
D

NTRA

Arincen62/100B
310.29
USD
-53.37
(-14.68%)
Post Trading·311.02USD+0.73(+0.24%)
Last updated: · Delayed 15 min
Q3 FY2026 results
EPS-0.42-49.3%Revenue793.98M+12.2%
OverviewFinancialsForecastEarningsCompany

Natera revenue 2012–2026

Natera's revenue in Q3 FY2026, the three months to 30 September 2026, was 793.98M USD, up 34.1% on the same quarter a year before. Natera's revenue over the last twelve months was 2.91B USD, up 37.4% on the twelve months before. In fiscal year 2025 it was 2.31B USD, up 35.9% on the year before.

Last updated 6 Nov 2026 · Next report 25 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 20262.91B+37.43%1.90B-164.71M
FY202531 Dec 20252.31B+35.90%1.50B-208.16M
FY202431 Dec 20241.70B+56.75%1.02B-190.43M
FY202331 Dec 20231.08B+31.99%492.74M-434.80M
FY202231 Dec 2022820.22M+31.13%363.97M-547.80M
FY202131 Dec 2021625.49M+59.97%307.07M-471.72M
FY202031 Dec 2020391.01M+29.33%187.39M-229.74M
FY201931 Dec 2019302.33M+17.34%126.86M-124.83M
FY201831 Dec 2018257.65M+22.15%91.60M-128.15M
FY201731 Dec 2017210.94M-2.83%71.34M-136.31M
FY201631 Dec 2016217.07M+14.04%81.50M-95.77M
FY201531 Dec 2015190.36M+19.50%77.51M-70.28M
FY201431 Dec 2014159.29M+188.72%80.89M-5.15M
FY201331 Dec 201355.17M+287.16%17.90M-37.11M
FY201231 Dec 201214.25M—3.10M-76.17M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Natera revenue growth by segment

Q3 FY2026 against Q3 FY2025

Product789.98M
+33.9%
Oncology600.00K
—

Natera revenue by segment over time

Product Licensing and other Hcs Qiagen Constellation Panorama Nipt Licensing And Other Other Genetic Tests Other Product Revenues Other Licensing And Other License And Development Services Upfront License And Constellation And Paternity Services Oncology products Genetic testing services
Fiscal yearProductLicensing and otherHcsQiagenConstellationPanorama NiptLicensing And OtherOther Genetic TestsOther Product RevenuesOther Licensing And OtherLicense And Development ServicesUpfront License And Constellation And Paternity ServicesOncology productsGenetic testing services
FY20252.30B +36.2%10.29M -13.0%— — — — — — — — — — — —
FY20241.69B +57.7%11.84M -15.7%— — — — — — — — — — — —
FY20231.07B +34.0%14.05M -38.7%— — — — — — — — — — 19.30M 18.30M
FY2022797.31M +40.6%22.92M -60.7%— — — — — — — — — — — —
FY2021567.15M +54.4%58.34M — — — — — — — — — — — —
FY2020367.21M +36.1%— — — — — 23.79M -26.7%— — — — — — —
FY2019269.88M +12.3%— — — — — 32.45M +87.7%— — 10.98M 16.38M 5.09M — —
FY2018240.37M — 87.17M 5.79M 4.84M 140.93M 17.29M 12.26M 6.65M — — — — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement

Common questions about Natera's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.